Bank of Montreal vs Inovio Pharmaceuticals Inc — how do they compare? Bank of Montreal trades at $182.04 (market cap $127.25B), while Inovio Pharmaceuticals Inc trades at $0.78 (market cap $76.09M). The key difference: Bank of Montreal is far larger — about 1672.4× Inovio Pharmaceuticals Inc's market cap, and Bank of Montreal pays a 2.68% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BMO | INO | |
|---|---|---|
Market Cap | $127.25B | $76.09M |
Sector | Financials | Health |
52-Week High | $183.65 | $2.87 |
52-Week Low | $112.54 | $0.66 |
Dividend Yield | 2.68% | — |
Enterprise Value | — | $47.10M |
Signals from Pluang's Aura AI — not financial advice
BMO trades at $181.55, up 0.4% with a bullish technical signal. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.66. Recent strategic moves include the $1.44 billion sale of Moneris and the acquisition of Euroz Hartleys' Australian capital markets business, strengthening its global metals and mining franchise. The stock shows strong fundamental performance with 25.92% net income margin and 11.05% ROE.
BMO presents a balanced investment case with solid earnings momentum and strategic expansion, though trading near resistance at $182. Key opportunities include consistent dividend payments and global banking recognition, while risks involve interest rate sensitivity and competitive pressures in the North American banking sector.
INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.
High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.
Trailing returns across standard periods
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →